Almost every research peptide is introduced by naming the receptor it acts on. That doesn't work for Ac-SDKP, its receptor has never been found. And that isn't a gap in the write-up; it is the most interesting thing about the molecule. Because the story of Ac-SDKP is defined not by what it binds, but by the enzyme that destroys it.

A peptide that a blood-pressure pill makes more of

Ac-SDKP (N-acetyl-Ser-Asp-Lys-Pro) is a natural tetrapeptide the body cleaves from a larger protein, thymosin β4. The main way the body clears it is angiotensin-converting enzyme (ACE), the very enzyme that millions of people with hypertension block every day.

That produces an unusual fact: when someone takes an ACE inhibitor, their own plasma Ac-SDKP rises roughly five-fold. Nothing is injected, the body simply stops destroying it. This led researchers to wonder whether part of the well-known protective effect of ACE inhibitors on the heart and kidney comes partly from lowering angiotensin II and partly from Ac-SDKP piling up. It's an elegant idea, but, to be honest, it has never been proven in humans. For now it's a plausible link, not an established fact.

Why anti-fibrosis

Fibrosis is what happens when, after injury, an organ replaces working tissue with scar. The central conductor of that process is a signalling protein, TGF-β1, which through intracellular Smad proteins orders fibroblasts to make collagen. In cell and rodent studies Ac-SDKP suppresses phosphorylation of Smad2, it intervenes in exactly this chain. Reduced scarring has been reported in models of the heart after infarction, the kidney in diabetes, and the lung in the bleomycin model.

This needs plain speaking: all of that is preclinical, dishes and animals. No clinical trial of Ac-SDKP for an antifibrotic indication has been run in humans. And antifibrotic research is notorious for effects that shine in mice and then fail repeatedly in people. So "reduces cardiac fibrosis" should be read as "reduced fibrosis in a rat model", not as a promise.

A history that ran backwards

Here is the strangest part. Usually a compound first shows an effect in a dish, then, at best, makes it to humans. With Ac-SDKP it went the other way: it has already been tested in humans, but for a completely different indication than the one it is known for now.

It was discovered in 1989 as a natural "brake" signal for blood-cell production: the peptide reversibly holds bone-marrow stem cells out of the dividing phase. From that came an elegant idea, chemoprotection. Chemotherapy hits dividing cells; if you temporarily put stem cells to sleep beforehand, the marrow should suffer less. Under the name goralatide, the compound reached phase I-II clinical studies in cancer patients back in the 1990s.

It never became a drug, and the main reason takes us right back to the start. The half-life of Ac-SDKP in blood is only about 4–5 minutes. That same ACE destroys it almost instantly. Administering a peptide that vanishes in minutes is a losing game.

The smartest conclusion: don't give the peptide, stop destroying it

Rather than fight the ultra-fast breakdown, researchers turned the problem around: if ACE clears Ac-SDKP, then selectively blocking only the part of the enzyme (the N-domain) that does this will raise a person's own Ac-SDKP, without the side effects tied to the other domain (dry cough, angioedema). The development of N-domain-selective ACE inhibitors, not administration of the peptide itself, is the main practical outcome of this whole story.

What to remember

  • Ac-SDKP is interesting not for a receptor (none found) but as the only natural specific substrate of the ACE N-domain.
  • ACE inhibitors raise its level ~5-fold, but its contribution to their clinical effect is unproven in humans.
  • The antifibrotic data are preclinical (heart, kidney, lung); there are no fibrosis clinical trials.
  • In humans it was only studied as goralatide for chemoprotection; its short half-life (~4–5 min) stopped development.

A detailed, source-referenced breakdown of the mechanism is in our Ac-SDKP monograph. Other approaches to the same target are in the Anti-fibrosis category, notably B7-33 (a relaxin analogue that works through a real receptor, the exact opposite of "receptor-less" Ac-SDKP).

See also: a general overview of AC-SDKP (goralatide) and what the tetrapeptide is.

Ac-SDKP is a research-use-only laboratory reagent. It is not a medicine or a dietary supplement, and it is not intended for human or animal consumption, diagnosis or treatment. This material is informational and is not medical advice.